ClinicalTrials.gg
CompletedNCT04998981Updated May 23, 2025

A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C

A Phase 3 interventional study of K-877 0.1 mg tablet and Fenofibrate 200 mg capsule in Hyperlipidemia, sponsored by Kowa Company, Ltd.. Completed at 33 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by Kowa Company, Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
353
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies in Hyperlipidemias with a site in China — 30 open to participants now, 37 under way, 7 of them phase 3. Hyperlipidemias · China.

Enrollment
19th of 78
353 · median 155
Started
2021
with 5 others
Phase 3
20 of 94
5 open now
Registered
32nd of 94
by date

Among the 94 studies in Hyperlipidemias with a site in China, this one is the 19th largest by enrollment of the 78 interventional ones that give a count, is one of 6 that started in 2021, is one of 20 in phase 3, and was the 32nd registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

30 of the 94 studies in Hyperlipidemias with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Hyperlipidemias with a site in China, or all of them as a file.
02

Study summary

A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients with High TG and Low HDL-C

03

Conditions studied

  • Hyperlipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects are eligible to be included in the study only if all of the following criteria apply:

  1. Ability to understand and comply with study procedures and give written
  2. Following the diet and lifestyle recommendations at least 12 weeks prior to the treatment period
  3. Males or females
  4. Aged ≥18 years at the time of informed consent
  5. Fasting serum TG levels ≥200 mg/dL (≥2.26 mmol/L) and ≤500 mg/dL (5.65 mmol/L) at screening
  6. Serum HDL-C \<50 mg/dL (\<1.30 mmol/L) if male or \<55 mg/dL (\<1.42 mmol/L) if female at screening.

Exclusion criteria

Exclusion Criteria:

Subjects are excluded from the study if any of the following criteria apply:

  1. Current or planned use of any lipid-altering medications other than the study drugs, statins, or ezetimibe during the study.

    i. Subjects currently on statins or ezetimibe must be at high risk for atherosclerotic CV diseases, and the dose(s) must be stable for at least 4 weeks prior to screening

    ii. For subjects currently on lipid-altering medications other than statins or ezetimibe, at least 4-week (or for subjects currently on probucol at least 8 week washout period) will be required prior to the first fasting blood sampling at Screening Visit

  2. Type 1 diabetes mellitus or poorly controlled Type 2 diabetes mellitus defined by (NGSP level) ≥8.0% at screening
  3. Uncontrolled hypertension defined by seated systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg at screening
  4. Uncontrolled thyroid disorder
  5. Creatinine ≥1.5 mg/dL at screening
  6. Severe hepatic disorder defined as cirrhosis of class B or C, or or ALT >2 × at screening
  7. History of pancreatitis
  8. Gallbladder disorder, history of cholelithiasis, primary biliary cirrhosis, or history of disease or surgery that may affect the absorption, distribution, metabolism and excretion of drugs or the metabolism of bile salts
  9. Unexplained creatine kinase (CK) >5 × ULN at screening
  10. Myocardial infraction or stroke (including ) within 3 months prior to the
  11. Class III or IV heart failure
  12. History of within 5 years
  13. Participation in another clinical study at the time of informed consent or administration of an drug other than placebo within 16 weeks prior to the informed consent for this study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
353 participants (actual)

Study arms

  • Experimental
    K-877 0.1 mg BID

    K-877 0.1 mg tablet twice daily, Placebo tablet twice daily, Placebo capsule once daily

    Drug: Placebo capsule · Drug: K-877 0.1 mg tablet · Drug: Placebo tablet

  • Experimental
    K-877 0.2 mg BID

    K-877 0.1 mg tablet x 2 twice daily, Placebo capsule once daily

    Drug: K-877 0.1 mg tablet · Drug: Placebo capsule

  • Active comparator
    Fenofibrate 200 mg QD

    Fenofibrate 200 mg capsule once daily, Placebo tablet x 2 twice daily

    Drug: Fenofibrate 200 mg capsule · Drug: Placebo tablet

  • Placebo comparator
    Placebo

    Placcebo tablet x 2 twice daily, Placebo capsule once daily

    Drug: Placebo tablet · Drug: Placebo capsule

Interventions

  • K-877 0.1 mg tablet x 2 twice daily

    Also known as: Pemafibrate

  • Fenofibrate 200 mg capsule once daily

  • DrugPlacebo tablet

    Placebo tablet x 2 twice daily

    Also known as: Placebo tablet (matching K-877)

  • DrugPlacebo capsule

    Placebo capsule once daily

    Also known as: Placebo capsule (matching fenofibrate)

  • K-877 0.1 mg tablet twice daily

    Also known as: Pemafibrate

  • DrugPlacebo tablet

    Placebo tablet twice daily

    Also known as: Placebo tablet (matching K-877)

06

What researchers measure

Primary outcomes

  1. Percent change in fasting TG versus placebo from baseline to Weeks 8 and 12

    Time frame: From baseline to Weeks 8 and 12

  2. Percent change in fasting TG versus fenofibrate from baseline to Weeks 8 and 12

    Time frame: From baseline to Weeks 8 and 12

Secondary outcomes

  1. Percentage of patients who have achieved fasting TG <150 mg/dL at the end of the treatment period

    Time frame: At Week 12

  2. Percent change from baseline to Weeks 8 and 12 in TC, LDL-C (direct method), LDL-C (Friedewald method), LDL-C (Martin/Hopkins equation), HDL-C (direct method), non-HDL-C (calculated), and remnant cholesterol (calculated)

    Time frame: From baseline to Weeks 8 and 12

  3. Change from baseline to Weeks 8 and 12 in fasting TG, TC, LDL-C (direct method), LDL-C (Friedewald method), LDL-C (Martin/Hopkins equation), HDL-C (direct method), non-HDL-C (calculated), and remnant cholesterol (calculated)

    Time frame: From baseline to Weeks 8 and 12

  4. Percent change from baseline to the end of the treatment period in Apo A1 and Apo B

    Time frame: From baseline to Week 12

  5. Percent change from baseline to the end of the treatment period in TG/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, LDL-C/HDL-C, LDL-C/Apo B, and Apo B/Apo A1

    Time frame: From baseline to Week 12

  6. The incidence of adverse events and adverse drug reactions after the administration of the study drug

    Time frame: Up to Week 12

  7. Change from baseline to Week 4, 8, and 12 in clinical laboratory tests (chemistry, hematology), vital signs (BP [mmHg], PR [bpm], weight [kg], waist [cm], and BMI [kg/m^2]; each parameter is evaluated individually.), 12-lead ECGs

    Time frame: From baseline to Week 4, 8, and 12

  8. Number and percentage of patients who experience laboratory abnormalities of special interest including, but not limited to ALT, AST, ALP, CK, and, creatinine during the treatment period

    Time frame: Up to Week 12

07

Study locations

33 sites
  • Huainan First People's Hospital
    Anhui, 232000, China
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, 100029, China
  • Beijing Hospital
    Beijing, 100730, China
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, 100730, China
  • Beijing Pinggu Hospital
    Beijing, 101200, China
  • Chengdu Xinhua Hospital
    Chengdu, 610066, China
  • The First Affiliated Hospital of Fujian Medical University
    Fujian, 350005, China
  • Peking Union Medical College Hospital
    Guangdong, 100032, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangdong, 510080, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangdong, 510120, China
  • The People's Hospital of Guangxi Zhuang Autonomous Region
    Guangxi, 530021, China
  • Hainan General Hospital
    Hainan, 570311, China
  • The Second Hospital of Hebei Medical University
    Hebei, 050000, China
  • The First Affiliated Hospital of Harbin Medical University
    Helongjiang, 150001, China
  • Union Hospital, Tongji Medical College of Huazhong University of Science & Technology
    Hubei, 430022, China
  • Tongji Hospital, Tongji Medical College of HUST
    Hubei, 430030, China
  • Shaanxi Provincial People's Hospital
    Hubei, 710068, China
  • The Third Xiangya Hospital of Central South University
    Hunan, 410013, China
  • The Third Hospital of Changsha
    Hunan, 410015, China
  • Nanjing Jiangning Hospital
    Jiangsu, 211100, China
  • Sir Run Run Hospital Nanjing Medical Universtiy
    Jiangsu, 211100, China
  • Affiliated Hospital of Jiangsu University
    Jiangsu, 212001, China
  • Jiangxi Provincial People's Hospital
    Jiangxi, 330006, China
  • The First Affiliated Hospital of Nanchang University
    Jiangxi, 330006, China
  • The First Hospital of Nanchang
    Jiangxi, 330008, China
  • Jiu Jiang No. 1 People's Hospital
    Jiangxi, 332000, China
  • Pingxiang People's Hospital
    Jiangxi, 337055, China
  • China-Japan Union Hospital of Jilin University
    Jilin, 330006, China
  • Shanghai Tongren Hospital
    Shanghai, 200336, China
  • People's Hospital of Deyang City
    Sichuan, 618000, China
  • Tianjin Union Medical Center
    Tianjin, 300121, China
  • The Affiliated Hospital of Hangzhou Normal University
    Zhejiang, 310015, China
  • People's Hospital of Wenzhou City
    Zhejiang, 325000, China
08

References and documents

Publications

  • Dai W, Lv Q, Li Q, Fu L, Zhang Y, Zhang Y, Liu L, Tanigawa R, Kunitomi K, Kamei R, Suganami H, Ma C. Efficacy and Safety of Pemafibrate, a Novel Selective PPARalpha Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial. J Atheroscler Thromb. 2025 Feb 1;32(2):125-140. doi: 10.5551/jat.64112. Epub 2024 Aug 2. PubMed 39098034 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Feb 2023, 16 months.

Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 16 months is below that.

Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2021
First posted
Aug 10, 2021
StartActual
Sep 17, 2021
Primary completionActual
Feb 2, 2023
CompletionActual
Feb 2, 2023
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04998981
Lead sponsor
Kowa Company, Ltd.
Responsible party
Sponsor
First posted
Aug 10, 2021
Start date
Sep 17, 2021
Primary completion
Feb 2, 2023
Completion
Feb 2, 2023
Last update
May 23, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemafibrate

Start the discussion